China SXT Pharmaceuticals Inc. (SXTC) gained 9.33% in the aftermarket, at $0.7898, versus its last close at $0.7224 on November 26. The stock went down by 4.93% in the previous trading session at a volume of 89.3 thousand. Intraday trading fluctuated between a high of $0.7798 and a low of $0.7128. While it saw a high of $5.1200 and a low of $0.7125 in the 52-week range. In the past week, the stock went down by 9.70% and 28.48% in the past month. Further, the SXTC stock has lost a value of 45.06% year to date. Moreover, the stock has 15.53 million outstanding shares, that trade at $11.22 million market capital. The recent gain in the stock seems to be an indication of recovery from its last profit booking event.
China SXT Pharmaceuticals Inc. (SXTC)
Founded IN 2005, China SXT Pharmaceuticals Inc. (SXTC) is a holding company that deals in traditional Chinese medicine pieces (TCMP). It researches, develops, manufactures, markets, and sells the TCMP. The company’s product categories include directly-oral, after-soaking-oral, fine, and regular TCMP. Its products are distributed under the brand name Suxuantang.
China SXT Pharmaceuticals Inc. (SXTC) is headquartered in Taizhou, the Peoples Republic of China.
SXTC’s stock Movement
During the month of October, the SXTC tock had been trading at a steady pace. But followed by the company’s announcement of a new permit and passed inspection on October 18, the stock gained some momentum. Following the news, the stock entered an uptrend which saw occasional loss due to profit booking events. The stock reached a high of $1.40 on October 26, which led to proper market corrections on the stock. As it entered a downtrend to reach $0.722 at the end of normal trading on November 26. This downtrend resulted in the stock losing 28.48% in the past month.
SXTC stock gained 9.33% in the after-hours on November 26, indicating that it is finally recovering as market sentiments are shifting in favor.
Permit and Inspection News
On November 18, China SXT Pharmaceuticals Inc. (SXTC) announced that it has received a new pharmaceutical manufacturing Permit and has passed its GMC Compliance-Inspection. The new pharmaceutical manufacturing permit (PMP) was received from Jiangsu Province Medical Products Administration (JSMPA). The permit is for new production scope of lyophilization processing, which is also called freeze-drying. This process not only improves the shelf life of products but also ensures better quality. SXTC also passed JSMPA’s compliance inspection for the new lyophilization production facility of the company.
